| Oct 11 |
US Growth Stocks With High Insider Ownership
|
| Oct 7 |
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
|
| Sep 27 |
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
|
| Sep 26 |
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
|
| Sep 25 |
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
|
| Sep 24 |
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
|
| Sep 21 |
Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble?
|
| Sep 20 |
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
|
| Sep 20 |
Longboard Stock Soars on FDA Designations for Epilepsy Drug
|
| Sep 20 |
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
|
